Testing metformin to reduce inflammation in breast cancer survivors with insulin resistance
Official title: Pilot Project 1
Funded at Beckman Research Institute/city of Hope · NIH-10933469 · Data updated 2026-11-12
This study is looking at how the diabetes medication metformin can help reduce inflammation in breast cancer survivors who have insulin resistance, and it's designed for those who want to see if this treatment can improve their health.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | September 22, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $111,020 |
| NIH project number | 5U54CA285116-02 |
| Project ID | NIH-10933469 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are breast cancer survivors who are insulin-resistant and may benefit from metformin treatment.
✕Less likely to help
Patients who do not have insulin resistance or are not breast cancer survivors may not receive any benefit from this research.
What this research studies
This research aims to build therapeutic trial capacity at the University of California, Riverside (UCR) by implementing a trial that investigates the effects of metformin on inflammation in breast cancer survivors who are insulin-resistant. The approach involves using advanced techniques like single-cell transcriptomics and ATAC sequencing to analyze the biological responses to treatment. The trial will be conducted at the City of Hope Comprehensive Cancer Center, leveraging their expertise and resources while providing training to UCR personnel. Patients will be monitored for changes in inflammatory markers and cellular responses to the treatment.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for breast cancer survivors suffering from insulin resistance.
How similar studies have gone: Previous research has shown promise in using metformin for reducing inflammation in similar patient populations, indicating potential for success in this approach.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Seewaldt, Victoria L. — Beckman Research Institute/city of Hope
- Study coordinator: Seewaldt, Victoria L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.